Quick answers
- What is Lasmiditan used for?
- The FDA-approved label (Reyvow, Eli Lilly and Company, January 8, 2026) says: “REYVOW ® is indicated for the acute treatment of migraine with or without aura in adults. REYVOW ® is a serotonin (5-HT) 1F receptor agonist indicated for the acute treatment of migraine with or without aura in adults. Limitations of Use REYVOW is not indicated for the preventive treatment of migraine. Limitations of Use REYVOW is not indicated for the preventive treatment of migraine.” This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
- Does Lasmiditan have a boxed warning?
- No. None of the 1 FDA labels we found for this medicine has a boxed warning.
- Is there a shortage of Lasmiditan?
- The FDA drug shortage list shows “To be discontinued” for a product of this medicine (updated November 3, 2025). Ask your pharmacist about alternatives.
- Has Lasmiditan been recalled?
- No recall linked to the products of this medicine appears in the FDA enforcement reports we use.
- Who makes Lasmiditan?
- 1 company lists prescription products of Lasmiditan in the FDA NDC Directory, including Eli Lilly and Company.
What Lasmiditan is used for
Quoted from the “Indications and Usage” section of the FDA-approved label.
REYVOW ® is indicated for the acute treatment of migraine with or without aura in adults. REYVOW ® is a serotonin (5-HT) 1F receptor agonist indicated for the acute treatment of migraine with or without aura in adults. Limitations of Use REYVOW is not indicated for the preventive treatment of migraine. Limitations of Use REYVOW is not indicated for the preventive treatment of migraine.
— FDA label: Reyvow, Eli Lilly and Company, effective January 8, 2026. Read the full label on DailyMed →
This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
Boxed warning
A boxed warning (“black box”) is the FDA’s strongest warning on a drug label, for serious or life-threatening risks.
The label quoted above has no boxed warning.
Forms and how it is given
| Dosage forms | Tablet |
|---|---|
| Route | Oral |
| Prescription products | 2 in the FDA NDC Directory |
| Brand names | Reyvow |
What pharmacies pay (NADAC)
The National Average Drug Acquisition Cost (NADAC) is the average price U.S. retail pharmacies paid to buy one unit of a medicine (one tablet, one mL or one gram), from a monthly survey of pharmacy invoices by the Centers for Medicare & Medicaid Services (CMS). State Medicaid programs use it to pay pharmacies.
This is not the price you pay. What you pay depends on your insurance (copay or coinsurance), your pharmacy and any discounts, and pharmacies also charge for filling a prescription. Ask your pharmacist or your health plan what your price will be.
| Strength and form | Generic or brand | Pharmacies pay |
|---|---|---|
| lasmiditan 100 mg tablet | Brand: Reyvow | $88.77 per tablet |
| lasmiditan 50 mg tablet | Brand: Reyvow | $88.70 per tablet |
NADAC list of November 4, 2026; these prices took effect on May 20, 2026. Shown only where a package’s NDC code matches the NADAC list exactly, and only for that exact strength and form: nothing is averaged across strengths. Strengths and forms not listed here have no NADAC price.
Source: NADAC (National Average Drug Acquisition Cost) 2026, data.medicaid.gov (CMS) →
Companies that list this medicine
Labelers in the FDA NDC Directory: the company named on the package (maker or distributor), with the number of prescription products.
- Eli Lilly and Company2 products
FDA approval history
- NDA: New Drug Application: how a new (usually brand-name) medicine is approved.
| Application | Sponsor | Approved | Later changes approved |
|---|---|---|---|
| NDA211280 REYVOW | Eli Lilly and Co | October 11, 2019 | 5, latest September 15, 2022 2022: Labeling · 2022: Labeling · 2022: Manufacturing (CMC) |
Shortage status
To be discontinued · updated November 3, 2025 · first posted November 3, 2025
| Product | Reyvow, Tablet, 100 mg (NDC 0002-4491-62) |
|---|---|
| Company | Eli Lilly and Co. |
Ask your pharmacist whether your product is affected and what the options are.
Recalls
No recall linked to these products (by their NDC code) appears in the FDA enforcement reports.
Official identifiers
| RxCUI (RxNorm) | 2256937, 2256943, 2256945, 2256947 |
|---|---|
| SPL set ID of the quoted label | aea3358c-ff41-4490-9e6d-c7bf7b3de13f |
| FDA labels (SPL) | 1 |
| FDA applications | NDA211280 |
| Active ingredients (FDA) | LASMIDITAN |
Sources
- FDA-approved label on DailyMed (National Library of Medicine) — Reyvow, Eli Lilly and Company, effective January 8, 2026; via openFDA, FDA data exported October 30, 2026, retrieved October 31, 2026
- NDC Directory (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
- Drugs@FDA (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
- Drug recall enforcement reports (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 27, 2026, retrieved October 31, 2026
- Drug shortages (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
openFDA data is provided by the FDA as is; it may be incomplete. Always rely on the label that comes with your medicine. FDA Enforcement Report search →